At the forefront of biomedical innovation, Charles River Laboratories International, Inc. is a pivotal force in accelerating the journey from scientific discovery to marketable therapies. Through groundbreaking technology and a comprehensive portfolio of services, the company is revolutionizing the drug discovery and development process for pharmaceutical and biotechnology companies, government agencies, and academic institutions across the globe. What began in 1947 as a one-person laboratory providing research models has evolved into a global strategic partner, instrumental in bringing new treatments to patients in need. The company's dedication to scientific advancement is evident in its continuous investment in cutting-edge methodologies and next-generation technologies, including the development and validation of non-animal testing methods to promote more ethical and efficient research.
Charles River's integrated approach spans the entire drug development continuum, from initial target identification and discovery services to non-clinical safety assessment and manufacturing support. This end-to-end capability, combined with a global network and the expertise of its scientific and regulatory advisors, empowers clients to navigate the complexities of the development process with greater speed and confidence. The company's commitment to innovation is further exemplified by its digital transformation initiatives, such as the Apollo™ platform, a secure cloud-based system designed to enhance client experience by providing greater access to data, products, and services. By fostering a culture of collaboration and scientific excellence, Charles River Laboratories is not just a service provider but a dedicated partner in the quest to create healthier lives, shaping the future of medicine one breakthrough at a time.